Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Supermax BhdSPMXF 50 Debt-to-EBITDA is -1.08 as of Mar. 2026. GuruFocus rates SPMXF with a GF Score™ of 50/100 and a GF Value™ of $0.40. The stock has 6 warning signs investors should review. Among 469 Medical Devices & Instruments companies, Supermax Bhd ranks worse than 213219.4% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Supermax Bhd's Debt-to-EBITDA or its related term are showing as below:
SPMXF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.37 Med: 0.32 Max: 2.81
Current: -0.49
During the past 13 years, the highest Debt-to-EBITDA Ratio of Supermax Bhd was 2.81. The lowest was -1.37. And the median was 0.32.
SPMXF's Debt-to-EBITDA is ranked worse than 100% of 469
companies
in the Medical Devices & Instruments industry
Industry Median: 1.6
vs SPMXF: -0.49
Supermax Bhd (OTCPK:SPMXF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Supermax Bhd Debt-to-EBITDA Related Terms
Supermax Bhd Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Supermax Bhd's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SPMXF vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Supermax Bhd's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supermax Bhd Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Supermax Bhd's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Supermax Bhd's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Supermax Bhd (SPMXF) has a Debt-to-EBITDA of -1.08 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Supermax Bhd. According to the industry distribution chart, Supermax Bhd ranks #999999 out of 469 companies in the Medical Devices & Instruments industry.
Is Supermax Bhd's Debt-to-EBITDA too high?
Supermax Bhd's current Debt-to-EBITDA is -1.08. Based on the distribution chart, Supermax Bhd ranks #999999 out of 469 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Supermax Bhd has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Supermax Bhd's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Supermax Bhd ranks #999999 out of 469 companies for Debt-to-EBITDA. This places Supermax Bhd in the lower half of its industry. The industry median Debt-to-EBITDA is 1.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Supermax Bhd. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Supermax Bhd's current Debt-to-EBITDA is -1.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supermax Bhd stock overvalued right now?
Supermax Bhd (SPMXF) has a current Debt-to-EBITDA of -1.08. The stock's GF Value™ is $0.40, compared to a current price of $0.15 — trading 62.5% below its estimated fair value. The current Debt-to-EBITDA is -1.08. Supermax Bhd's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Supermax Bhd (SPMXF), the current Debt-to-EBITDA is -1.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Supermax Bhd (SPMXF) Overvalued in 2026?
Based on GuruFocus' analysis, Supermax Bhd stock appears to be undervalued.
The current stock price of $0.15 is trading 62.5% below its estimated GF Value™ of $0.40.
Key valuation signals for SPMXF:
Debt-to-EBITDA: -1.08
GF Value™: $0.40 vs. price of $0.15 (62.5% below fair value)
No single metric tells the full story. See the SPMXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Supermax Corp Bhd is an investment holding company. Along with its subsidiaries, the company operates as an international manufacturer, distributor, and marketer of high-quality medical gloves and contact lenses. It offers various types of latex gloves, which are exported to numerous countries. The company is organized into the following reportable operating segments: manufacturing of gloves, which generates the majority of revenue; investment holding; trading of gloves; and others. Geographically, it derives the majority of its revenue from Europe, with the remainder coming from Africa, Asia and Oceania, and North, Central, and South America.
50GF Score
Get the complete analysis for SPMXF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPMXF has been successfully added to your 
